This trial is studying the effect of CPX-351 followed by donor stem cell transplantation compared to immediate donor stem cell transplantation in treating patients with high-grade myeloid cancers that still have some measureable disease.
1 Primary · 3 Secondary · Reporting Duration: Up to 5 years post-randomization
1 Total Participants · 2 Treatment Groups
Primary Treatment: Allogeneic Hematopoietic Stem Cell Transplantation · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: